BPC-157 (Pentadecapeptide)

Body Protection Compound: A Name That Is a Hypothesis

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library2 min readLast reviewed 2026-08-233 cited sources

The short answer

The Zagreb group named the gastric juice protein body protection compound to reflect a hypothesised protective role. The name records a hypothesis from the time of discovery rather than a demonstrated function, and it has carried an implicit claim ever since.

Key facts

Named by
The Zagreb research group
Refers to
A protein in human gastric juice
BPC-157
A 15-residue partial sequence of it
The name asserts
A protective function
Status of that claim
Preclinical; one Phase 2 recruiting
Comparable case
Delta sleep-inducing peptide

The reasoning behind the name

Gastric juice is a hostile environment (strongly acidic and rich in proteases), and the stomach lining survives it. That observation invites the hypothesis that something in gastric juice is protective, and a protein isolated from it that appeared to have protective effects in lesion models was named accordingly.

What a functional name does to a reader

It supplies a conclusion before any evidence is examined. Body protection compound sounds like a description; it is a proposal. The same is true of delta sleep-inducing peptide, and of liver cell growth factor, GHK's original name. All three were named for what an investigator believed they had found. Two of those names did not survive scrutiny.

Research material referenced

BPC-157 5mg, third-party HPLC tested

Buy BPC-157 · £16.95

How BPC-157 differs from those cases

It has more behind it. DSIP has no gene, no receptor and an unresolved central claim. GHK's early name was abandoned once its actual chemistry became clear. BPC-157 has a large preclinical literature across multiple model systems, earlier clinical development as PL-14736, and a randomised placebo-controlled Phase 2 recruiting now. The name is still a hypothesis, but the hypothesis is being tested properly.

What would settle it

NCT07437547: a randomised, double-blind, placebo-controlled Phase 2 trial in 120 participants with acute hamstring strain, sponsored by a party unconnected to the original research group, with primary completion due 14 February 2027. That design is what converts a hypothesis into a result, whichever direction it goes.

The position until then

The name is not evidence. The preclinical literature is substantial but concentrated in one group. The clinical evidence is a completed Phase 1 and a Phase 2 that has not reported. That is an interesting position for a research compound to be in, and it is not the same as a demonstrated protective effect in anyone.

Frequently asked questions

Does the name mean BPC-157 protects the body?

No. It records a hypothesis the Zagreb group formed at discovery. Names of that kind assert a function rather than describe a demonstrated one.

Is the hypothesis being tested?

Yes. NCT07437547 is a randomised, double-blind, placebo-controlled Phase 2 trial with primary completion due February 2027.

How does this compare to DSIP?

Both are named for a proposed function. DSIP has no gene, no receptor and no clinical programme; BPC-157 has a large preclinical literature and registered trials.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More BPC-157 (Pentadecapeptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.